Paloma Partners’s GoodRx Holdings GDRX Stock Holding History

Paloma Partners’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,300	Closed	-$108K	–	1135
2022 Q2	$108K	Buy	+18,300	New	+$204K	﹤0.01%	960
2022 Q1	–	Sell	-12,500	Closed	-$409K	–	1932
2021 Q4	$409K	Buy	+12,500	New	+$503K	0.01%	1218

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

Paloma Partners's GDRX Position: Q3 2022 in Review

Paloma Partners sold out of GoodRx Holdings (GDRX) in Q3 2022, closing a stake of 18,300 shares — an estimated $108K sold.

Paloma Partners first reported a position in GDRX in Q4 2021 and held it in 2 quarters. The position peaked at $409K in Q4 2021. 180 funds tracked by Wall St. Rank hold GDRX as of Q3 2022.

Paloma Partners reported no remaining GoodRx Holdings position as of Q3 2022 after selling out during the quarter.
Paloma Partners sold 18,300 GoodRx Holdings shares in Q3 2022, an estimated $108K.
Paloma Partners first reported a position in GoodRx Holdings in Q4 2021 and held it in 2 quarters.
Paloma Partners's GoodRx Holdings position peaked at $409K in Q4 2021.
180 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2022.

Based on Paloma Partners's 13F filing for Q3 2022, filed 14 Nov 2022.